New Weight-Loss drug HS235 passes early safety check in small study
NCT ID NCT06714825
First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This early-stage study tested a new drug called HS235 in 39 overweight or obese but otherwise healthy adults aged 40 and older. The main goal was to check the drug's safety and how the body processes it, not to prove weight loss. Researchers gave single and multiple doses to see if it caused any side effects. This is a first step to see if HS235 might help with weight management in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Syneos Clinical Research Unit
Québec, Quebec, Canada
Conditions
Explore the condition pages connected to this study.